Inhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe Purchases 9,500 Shares

Inhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe purchased 9,500 shares of the stock in a transaction on Monday, September 9th. The stock was acquired at an average cost of $15.21 per share, with a total value of $144,495.00. Following the completion of the purchase, the chief executive officer now directly owns 657,048 shares of the company’s stock, valued at $9,993,700.08. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Mark Lappe also recently made the following trade(s):

• On Friday, September 6th, Mark Lappe acquired 26,000 shares of Inhibrx stock. The stock was bought at an average price of $15.29 per share, for a total transaction of $397,540.00.
• On Tuesday, September 3rd, Mark Lappe bought 20,000 shares of Inhibrx stock. The shares were bought at an average price of $15.81 per share, with a total value of $316,200.00.
• On Thursday, August 29th, Mark Lappe purchased 10,000 shares of Inhibrx stock. The stock was bought at an average cost of $14.03 per share, for a total transaction of $140,300.00.

Inhibrx Price Performance

Shares of INBX stock traded down $0.02 during mid-day trading on Tuesday, reaching $15.18. The stock had a trading volume of 72,666 shares, compared to its average volume of 177,810. The stock’s 50-day moving average price is $13.47 and its two-hundred day moving average price is $24.38. Inhibrx, Inc. has a 52-week low of $10.80 and a 52-week high of $18.95.

Inhibrx (NASDAQ:INBX) last announced its quarterly earnings results on Tuesday, August 13th. The company reported $125.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.60) by $129.08. The business had revenue of $0.10 million for the quarter. As a group, equities analysts predict that Inhibrx, Inc. will post 87.5 earnings per share for the current year.

Hedge Funds Weigh In On Inhibrx

Several hedge funds have recently made changes to their positions in INBX. Quadrant Capital Group LLC purchased a new stake in Inhibrx in the fourth quarter worth $26,000. HCR Wealth Advisors purchased a new position in Inhibrx during the 4th quarter valued at $239,000. China Universal Asset Management Co. Ltd. raised its holdings in Inhibrx by 66.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,106 shares of the company’s stock worth $318,000 after purchasing an additional 3,635 shares in the last quarter. Fifth Lane Capital LP purchased a new stake in shares of Inhibrx in the 1st quarter worth about $357,000. Finally, Entropy Technologies LP bought a new stake in shares of Inhibrx during the 1st quarter valued at about $384,000. 82.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, JMP Securities initiated coverage on shares of Inhibrx in a report on Tuesday, July 23rd. They issued a “market perform” rating on the stock.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.